151 related articles for article (PubMed ID: 31769341)
1.
Wei X; Cai J; Zhuang J; Zheng B; Sui Y; Zhang G; Lin Y; Sun H
Pharmacogenomics; 2020 Jan; 21(1):43-53. PubMed ID: 31769341
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
5. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Woods B; Veenstra D; Hawkins N
Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
7. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Chlebowski RT; Col N
J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
[No Abstract] [Full Text] [Related]
8. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Hayes DF; Stearns V; Rae J; Flockhart D;
J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
[No Abstract] [Full Text] [Related]
9. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
Johnson JA; Hamadeh IS; Langaee TY
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638249
[No Abstract] [Full Text] [Related]
10. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
11. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
Higgins MJ; Stearns V
Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
[No Abstract] [Full Text] [Related]
12. Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.
Wang H; Ma X; Zhang B; Zhang Y; Han N; Wei L; Sun C; Sun S; Zeng X; Guo H; Li Y; Zhang Y; Zhao J; Qin Z; Liu Z; Zhang N
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e148-e153. PubMed ID: 34196110
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
Rae JM; Sikora MJ; Henry NL; Li L; Kim S; Oesterreich S; Skaar TC; Nguyen AT; Desta Z; Storniolo AM; Flockhart DA; Hayes DF; Stearns V;
Pharmacogenomics J; 2009 Aug; 9(4):258-64. PubMed ID: 19421167
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
17. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
Thota K; Prasad K; Basaveswara Rao MV
Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
[TBL] [Abstract][Full Text] [Related]
19. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
Brauch H; Schwab M
Br J Clin Pharmacol; 2014 Apr; 77(4):695-703. PubMed ID: 24033728
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
Kaplan M; Mahon SM
Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]